PMID- 34826969
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20220308
IS  - 1998-3689 (Electronic)
IS  - 0301-4738 (Print)
IS  - 0301-4738 (Linking)
VI  - 69
IP  - 12
DP  - 2021 Dec
TI  - Mitomycin C application after photorefractive keratectomy in high, moderate, or 
      low myopia: Systematic review and meta-analysis.
PG  - 3421-3431
LID - 10.4103/ijo.IJO_3768_20 [doi]
AB  - Photorefractive keratectomy (PRK) is considered a safe approach laser procedure 
      with a clinical significance in correcting myopia results. PRK requires removing 
      the whole superficial epithelium. The integrity of the epithelial basement 
      membrane and the deposition of abnormal extracellular matrix can put the cornea 
      in a probable situation for corneal haze formation. Mitomycin C (MMC) is applied 
      after excimer laser ablation as a primary modulator for wound healing, limiting 
      corneal haze formation. We aim to summarize the outcomes of MMC application after 
      laser ablation. We searched Scopus, PubMed, Cochrane CENTRAL, and Web of Science 
      till December 2020 using relevant keywords. The data were extracted and pooled as 
      mean difference (MD) or risk ratio (RR) with a 95% confidence interval (CI), 
      using Review Manager software (version 5.4). Our analysis demonstrated a 
      statistically significant result for MMC application over the control group in 
      terms of corneal haze formation postoperatively (RR = 0.29, 95% CI: [0.19, 0.45], 
      P < 0.00001). Regarding corrected distance visual acuity (CDVA), no significant 
      difference was observed between the MMC group and the control group (MD = 0.02; 
      95% CI: [-0.04, 0.07]; P = 0.56). Regarding the uncorrected distance visual 
      acuity (UDVA), the analysis favored the MMC application with (MD -0.03, 95% CI: 
      [-0.06, -0.00]; P = 0.05). There was no statistically significant increase in 
      complications with MMC. In conclusion, MMC application after PRK is associated 
      with a lower incidence of corneal haze formation with no statistically 
      significant side effects. The long term effect can show improvement regarding 
      UDVA favoring MMC. However, there is no significant effect of MMCs application 
      regarding CDVA, and SE.
FAU - Ouerdane, Yassamine
AU  - Ouerdane Y
AD  - Faculty of Medicine, Saad Dahlab University, Blida, Algeria; International 
      Medical Research Association (IMedRA), Egypt.
FAU - Zaazouee, Mohamed Sayed
AU  - Zaazouee MS
AD  - Faculty of Medicine, Al-Azhar University, Assiut; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Mohamed, Moaiad Eldin Ahmed
AU  - Mohamed MEA
AD  - Faculty of Medicine, Assiut University, Assiut; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Hasan, Mohammed Tarek
AU  - Hasan MT
AD  - Faculty of Medicine, Al-Azhar University, Cairo; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Hamdy, Mohamed
AU  - Hamdy M
AD  - Faculty of Medicine, Al-Azhar University, Cairo; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Ghoneim, Abdallah Magdy
AU  - Ghoneim AM
AD  - Faculty of Medicine, Al-Azhar University, Cairo; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Gbreel, Mohamed Ibrahim
AU  - Gbreel MI
AD  - Faculty of Medicine, October 6 University, Giza; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Ibrahim, Ahmed Mohamed
AU  - Ibrahim AM
AD  - Faculty of Medicine, Al-Azhar University, Cairo; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Ragab, Khaled Mohamed
AU  - Ragab KM
AD  - Faculty of Medicine, Minia University, Minia; International Medical Research 
      Association (IMedRA), Egypt.
FAU - Nourelden, Anas Zakarya
AU  - Nourelden AZ
AD  - Faculty of Medicine, Al-Azhar University, Cairo; International Medical Research 
      Association (IMedRA), Egypt.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - India
TA  - Indian J Ophthalmol
JT  - Indian journal of ophthalmology
JID - 0405376
RN  - 0 (Alkylating Agents)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Alkylating Agents
MH  - Humans
MH  - Lasers, Excimer/therapeutic use
MH  - Mitomycin
MH  - *Myopia/surgery
MH  - *Photorefractive Keratectomy
PMC - PMC8837284
OTO - NOTNLM
OT  - Corneal haze
OT  - meta-analysis
OT  - mitomycin C (MMC)
OT  - photorefractive keratectomy (PRK)
COIS- None
EDAT- 2021/11/28 06:00
MHDA- 2021/12/15 06:00
PMCR- 2021/12/01
CRDT- 2021/11/27 01:01
PHST- 2021/11/27 01:01 [entrez]
PHST- 2021/11/28 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/12/01 00:00 [pmc-release]
AID - IndianJOphthalmol_2021_69_12_3421_331033 [pii]
AID - IJO-69-3421 [pii]
AID - 10.4103/ijo.IJO_3768_20 [doi]
PST - ppublish
SO  - Indian J Ophthalmol. 2021 Dec;69(12):3421-3431. doi: 10.4103/ijo.IJO_3768_20.